Literature DB >> 4905235

Some approaches to the therapeutic exploitation of metabolic sites of vulnerability of neoplastic cells.

A C Sartorelli.   

Abstract

Mesh:

Substances:

Year:  1969        PMID: 4905235

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


× No keyword cloud information.
  8 in total

1.  Comparison of the antiviral effects of 5-methoxymethyl-deoxyuridine with 5-iododeoxyuridine, cytosine arabinoside, and adenine arabinoside.

Authors:  L A Babiuk; B Meldrum; V S Gupta; B T Rouse
Journal:  Antimicrob Agents Chemother       Date:  1975-12       Impact factor: 5.191

2.  [Therapeutic trials with cytostatics (author's transl)].

Authors:  H O Klein
Journal:  Blut       Date:  1977-08-29

3.  Combination chemotherapy: interaction of 5-methoxymethyldeoxyuridine with adenine arabinoside, 5-ethyldeoxyuridine, 5-iododeoxyuridine, and phosphonoacetic acid against herpes simplex virus types 1 and 2.

Authors:  N K Ayisi; V S Gupta; J B Meldrum; A K Taneja; L A Babiuk
Journal:  Antimicrob Agents Chemother       Date:  1980-04       Impact factor: 5.191

4.  Effect of ribonucleotide reductase inhibitors on the growth of human colon carcinoma HT-29 cells in culture.

Authors:  M Matsumoto; T Tihan; J G Cory
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

5.  Purine nucleotide synthesis in normal and leukemic blood cells.

Authors:  H Becher; M Weber; G W Löhr
Journal:  Klin Wochenschr       Date:  1978-03-15

6.  On the Design of Combination Cancer Therapy.

Authors:  James H Doroshow; Richard M Simon
Journal:  Cell       Date:  2017-12-14       Impact factor: 41.582

7.  Analyses of the combination of 6-MP and dasatinib in cell culture.

Authors:  Gurmeet Kaur; Holger Behrsing; Ralph E Parchment; Myrtle Davis Millin; Beverly A Teicher
Journal:  Int J Oncol       Date:  2013-05-02       Impact factor: 5.650

Review 8.  Cutting down the time to identify challenging tumor therapeutic targets and drug combinations using synthetic lethal approaches.

Authors:  John S Lazo
Journal:  F1000Res       Date:  2018-03-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.